- Conditions
- Cervical Cancer
- Interventions
- Velcade (bortezomib), Irinotecan
- Drug
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 921
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
- Interventions
- Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 847 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 72
- States / cities
- Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
- Conditions
- Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Interventions
- Nab paclitaxel, Gemcitabine, Radiological Assessments, mFOLFIRINOX
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Winston-Salem, North Carolina
- Conditions
- Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
- Interventions
- Temozolomide, Bevacizumab, Irinotecan
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cincinnati, Ohio
- Conditions
- Oncology
- Interventions
- Napabucasin, Nab-paclitaxel, Gemcitabine, Nivolumab, Paclitaxel, Irinotecan, Leucovorin, 5Fluorouracil, Bevacizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Scarborough, Maine • Portland, Oregon
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
- Interventions
- Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 100 more
- Conditions
- Childhood CNS Tumor
- Interventions
- SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
- Genetic · Radiation · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1570, pembrolizumab, Trifluridine + Tipiracil, Bevacizumab, Docetaxel, Oxaliplatin, Leucovorin, 5-Fluorouracil, Irinotecan, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 12
- States / cities
- Fullerton, California • Los Angeles, California • Sarasota, Florida + 8 more
- Conditions
- Sarcoma
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Herbert Irving Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colon Cancer, Colorectal Cancer
- Interventions
- MRTX849, Irinotecan, Cetuximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 47
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Neuroblastoma
- Interventions
- 131I-MIBG, Vincristine, Irinotecan, Vorinostat
- Radiation · Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
- Conditions
- Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
- Interventions
- Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
- Drug
- Lead sponsor
- Cardiff Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
- Conditions
- Adenocarcinoma of Esophagus, Squamous Cell Carcinoma of Esophagus
- Interventions
- Cetuximab, Cisplatin, Irinotecan, Radiation therapy, Surgery
- Drug · Device · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Adenocarcinoma of the Pancreas
- Interventions
- Surgical resection
- Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
- Interventions
- Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 1,656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 154
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Pineoblastoma, Primary Central Nervous System Neoplasm, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
- Interventions
- Adavosertib, Irinotecan Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
- Interventions
- VAL-413, Temozolomide
- Drug
- Lead sponsor
- Valent Technologies, LLC
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Colorectal Cancer
- Interventions
- Stool Collection and Survey Completion
- Other
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Glioblastoma Multiforme, Glioma
- Interventions
- Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST)
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Biliary Tract Cancer
- Interventions
- Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil, Leucovorin
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Grand Rapids, Michigan • Salt Lake City, Utah + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York